Filing Analysis
Picard Medical, Inc. announced the immediate termination of its Chief Financial Officer, Bernard Skaggs, on June 1, 2026. Simultaneously, the company appointed Georgina Smith as Chief Accounting Officer.
🚩 Red Flags
- Immediate termination of the CFO is a significant red flag for micro-cap companies, often signaling internal disputes, financial irregularities, or governance failures.
- The company has appointed a Chief Accounting Officer (CAO) but has not named a new Chief Financial Officer (CFO), leaving a critical executive vacancy.
📋 Key Facts
- Bernard Skaggs was terminated as CFO effective June 1, 2026.
- Georgina Smith was appointed as Chief Accounting Officer effective June 1, 2026.
- Georgina Smith previously served as Controller of SynCardia Systems, LLC (a company subsidiary) from January 2026 to May 2026.
- Ms. Smith is a CPA with previous experience at Rain Bird Corporation and Tucson Electric Power.
Picard Medical, Inc. filed an 8-K to furnish a press release containing a letter from Chairman Richard Fang to stockholders. The filing is specifically designated as 'furnished' rather than 'filed', reducing the legal liability associated with the content.
📋 Key Facts
- Date of report: May 29, 2026
- The filing includes a press release (Exhibit 99.1) featuring a letter from Chairman Richard Fang
- The company is an emerging growth company
- The report is furnished under Item 7.01 of the 8-K
Picard Medical, Inc. (PMI) received two separate NYSE American non-compliance notices — on May 8 and May 15, 2026 — for failing to meet continued listing standards related to minimum stockholders' equity. The company reported a stockholders' deficit of approximately $1.4 million as of March 31, 2026, and has incurred net losses in each of its three most recent fiscal years. PMI must submit a compliance plan by June 7, 2026, or face delisting procedures, with a final compliance deadline of November 8, 2027.
🚩 Red Flags
- Two separate NYSE American non-compliance notices received within 7 days (May 8 and May 15, 2026), indicating multiple listing standard failures simultaneously.
- Stockholders' deficit of approximately $1.4 million — not merely insufficient equity, but negative equity, falling $3.4 million short of the $2.0 million minimum requirement.
- Net losses reported in all three most recent fiscal years (FY2023, FY2024, FY2025), demonstrating a persistent inability to achieve profitability.
- '.BC' designation added to ticker symbol, publicly flagging non-compliance status to market participants.
- Delisting risk is real and time-bound: failure to submit or execute an acceptable plan by November 8, 2027 triggers formal delisting procedures.
- Multiple 8-K items (2.02, 3.01, 7.01) filed simultaneously, suggesting compounding operational and financial pressures.
- As an emerging growth company with negative equity, access to capital markets to remediate compliance may be severely constrained.
📋 Key Facts
- May 15, 2026: NYSE American issued notice of non-compliance with Section 1003(a)(i) of the NYSE American Company Guide, requiring at least $2.0 million in stockholders' equity for companies with recent losses.
- May 8, 2026: A prior notice was received for non-compliance with Section 1003(a)(ii) — a second, distinct listing standard violation.
- Reported stockholders' deficit of approximately $1.4 million as of March 31, 2026.
- Company has incurred losses from continuing operations and/or net losses in all three most recent fiscal years ended December 31, 2025.
- PMI must submit a compliance plan (the 'Plan') to NYSE American by June 7, 2026.
- If the Plan is accepted, compliance must be achieved by November 8, 2027, or delisting procedures will commence.
- Common stock continues to trade on NYSE American under 'PMI' but with added '.BC' designation (applied following the May 8 Notice), signaling non-compliance status.
- Filing covers Items 2.02, 3.01, 7.01, and 9.01 — four items in a single 8-K.
- Company is an emerging growth company incorporated in Delaware, headquartered in Tucson, AZ.
- CEO Patrick NJ Schnegelsberg signed the filing dated May 21, 2026.
Picard Medical, Inc. entered into a $5.0 million registered public offering at $0.30 per share and subsequently received a delisting notice from NYSE American for failing to maintain the minimum stockholders' equity requirement of $4.0 million.
🚩 Red Flags
- NYSE American delisting notice for equity deficiency
- Stockholders' equity of $3.8M is below the $4.0M exchange requirement
- Highly dilutive offering at a low price of $0.30 per share
- History of losses in three of the last four fiscal years
- Multiple 8-K items (1.01 and 3.01) filed simultaneously
📋 Key Facts
- On May 5, 2026, the Company agreed to a registered public offering of 16,666,667 shares and warrants at a combined price of $0.30 per unit.
- Gross proceeds from the offering are approximately $5.0 million before expenses.
- On May 8, 2026, NYSE American notified the Company of non-compliance with Section 1003(a)(ii) regarding stockholders' equity.
- Stockholders' equity was reported at $3.8 million as of December 31, 2025, below the $4.0 million requirement.
- The Company has incurred net losses in three of its four most recent fiscal years.
- A compliance plan must be submitted by June 7, 2026.
Picard Medical, Inc. entered into a Warrant Issuance and Exchange Agreement to reprice and increase the volume of outstanding warrants. The company is exchanging 7,009,346 warrants with a $2.675 exercise price for 10,000,000 new warrants with a significantly lower exercise price of $0.35.
🚩 Red Flags
- Massive reduction in warrant exercise price ($2.675 to $0.35) indicates a severe decline in company valuation since December 2025.
- Significant potential dilution of 10,000,000 shares.
- The repricing appears necessary to facilitate a new capital raise (S-1 offering), suggesting financial distress or lack of investor interest at higher prices.
📋 Key Facts
- Agreement dated May 5, 2026, with a holder of warrants originally issued in December 2025.
- Exercise price reduced from $2.675 to $0.35 per share, an 87% reduction.
- Number of shares issuable upon exercise increased from 7,009,346 to 10,000,000.
- The exchange is contingent upon the closing of a current registered offering on Form S-1 (File No. 333-295333).
- New warrants eliminate broad-based anti-dilution price protection and forced exercise provisions.
- The new warrants have a five-year term and include a 9.99% beneficial ownership limitation.
Picard Medical, Inc. announced preliminary unaudited top-line revenue results for its first fiscal quarter ended March 31, 2026. The disclosure was made via a press release furnished under Item 2.02.
📋 Key Facts
- The filing reports preliminary revenue for the quarter ended March 31, 2026.
- The information is furnished under Item 2.02 and is not deemed 'filed' for Section 18 purposes.
- The report was signed by CEO Patrick NJ Schnegelsberg on April 22, 2026.
- The company is classified as an emerging growth company.
Picard Medical, Inc. entered into a $555,555.56 convertible promissory note agreement with Quick Capital, LLC, receiving net proceeds of only $490,000 after discounts and fees. The agreement includes highly dilutive default provisions and restricts the company's ability to pay dividends while the debt is outstanding.
🚩 Red Flags
- High cost of capital: The company is paying effectively $65,555 in fees/discounts plus $66,666 in interest to net $490,000.
- Predatory conversion terms: The 25% discount to the lowest 10-day trading price upon default is characteristic of 'death spiral' financing.
- Aggressive repayment schedule: Monthly payments of ~$103k begin just three months after issuance for a nine-month note.
- Restrictive covenants: The company is prohibited from paying dividends or making distributions without buyer consent.
- Default multiplier: A 150%-200% penalty on principal upon default is extremely punitive.
📋 Key Facts
- Principal amount of the Note is $555,555.56 with an original issue discount (OID) of $55,555.56.
- Actual cash consideration received by the Company was $490,000 after OID and $10,000 in buyer expenses.
- A one-time interest charge of 12% ($66,666.67) was applied on the issuance date of April 7, 2026.
- The Company issued 80,128 shares of common stock as 'Origination Shares' to the buyer.
- Repayment consists of six equal monthly installments of $103,703.70 starting July 1, 2026.
- Upon default, the Note is convertible at 75% of the lowest trading price during the 10 trading days prior to conversion.
- Default penalties include the Note becoming due at 150% to 200% of the outstanding principal.
Picard Medical, Inc. held an earnings conference call on March 25, 2026, to discuss its financial and operating results for the fiscal year ended December 31, 2025. The company furnished the presentation materials used during the call as an exhibit to the filing.
📋 Key Facts
- Earnings call held on March 25, 2026
- Discussion focused on fiscal year ended December 31, 2025
- Exhibit 99.1 contains the earnings conference call presentation
- Company is an emerging growth company listed on NYSE American
Picard Medical, Inc. (PMI) reported its financial and operating results for the fiscal year ended December 31, 2025. The announcement was made via a press release on March 25, 2026, and furnished under Item 2.02.
📋 Key Facts
- Fiscal year ended December 31, 2025 results announced.
- Press release dated March 25, 2026, furnished as Exhibit 99.1.
- Registrant is an emerging growth company listed on NYSE American under ticker 'PMI'.
- The filing was signed by CEO Patrick NJ Schnegelsberg.
Picard Medical, Inc. announced its upcoming participation in the American College of Cardiology’s Annual Scientific Session & Expo in late March 2026.
📋 Key Facts
- The Company will participate in the American College of Cardiology’s Annual Scientific Session & Expo.
- The event is scheduled to take place from March 28 to March 30, 2026.
- The conference will be held in New Orleans, Louisiana.
- The disclosure was made under Item 7.01 (Regulation FD Disclosure).
Picard Medical, Inc. issued a press release announcing a clinical milestone where its SynCardia Total Artificial Heart successfully sustained a patient for 119 days while awaiting a donor transplant.
📋 Key Facts
- The report was filed on March 19, 2026, under Item 7.01 Regulation FD Disclosure.
- The SynCardia Total Artificial Heart was used to bridge a patient to transplant for a duration of 119 days.
- The press release (Exhibit 99.1) details the successful outcome of the patient receiving a donor heart.
- The company is an emerging growth company listed on the NYSE American under the ticker PMI.
Picard Medical announced a clinical milestone where a patient was successfully sustained by the SynCardia Total Artificial Heart for over 1,600 days (more than four years) prior to a successful heart transplant. The disclosure highlights the long-term durability and efficacy of the company's core medical device technology.
📋 Key Facts
- A 29-year-old patient was implanted with the SynCardia Total Artificial Heart on September 2, 2021.
- The patient underwent a successful heart transplant on February 24, 2026.
- The device provided continuous support for over 1,600 days, demonstrating significant long-term reliability.
- The information was furnished under Item 7.01 and is not deemed 'filed' for purposes of Section 18 of the Exchange Act.
Picard Medical stockholders approved a 100% increase in authorized common shares and cleared the way for a major stock issuance to High Trail entities. The move allows the company to issue shares exceeding 20% of its current outstanding stock, signaling significant upcoming dilution.
🚩 Red Flags
- 100% increase in authorized common stock (from 150M to 300M) indicates massive potential dilution.
- Approval of >20% issuance to High Trail entities, which are frequently associated with structured, highly dilutive financing arrangements.
📋 Key Facts
- Authorized common stock increased from 150,000,000 to 300,000,000 shares.
- Stockholders approved the issuance of shares exceeding 20% of outstanding stock to HT Investments MA LLC and High Trail Special Situations LLC per NYSE American Rule 713.
- As of the February 6, 2026 record date, there were 73,701,176 shares of common stock outstanding.
- The special meeting was held on March 10, 2026, with approximately 57.16% of shares represented.
Picard Medical, Inc. announced that it will be featured in a television segment on BTV – Business Television, airing on FOX Business News on March 14, 2026. The broadcast will highlight the company's SynCardia Total Artificial Heart (TAH) and its development of next-generation artificial heart technology.
📋 Key Facts
- The company will be featured on BTV – Business Television on March 14, 2026, at 5:00 p.m. ET.
- The segment will air on FOX Business News.
- The focus of the media coverage is the SynCardia Total Artificial Heart (TAH) and future technology developments.
- The disclosure was made under Item 7.01 (Regulation FD Disclosure).
Picard Medical, Inc. announced it will host an Annual Business Update webcast on March 25, 2026, to review its fiscal year and fourth quarter 2025 financial results.
📋 Key Facts
- The webcast is scheduled for March 25, 2026, at 4:30 p.m. Eastern Time.
- Management will discuss operational progress, commercial activity, and strategic priorities.
- The presentation will feature perspectives on the SynCardia Total Artificial Heart, including clinician views and a patient testimonial.
- The filing includes a press release as Exhibit 99.1.
Picard Medical, Inc. announced that its Vice President of Clinical Affairs, Dr. Andre Simon, will deliver three presentations at the Technology and Heart Failure Therapeutics 2026 conference in Boston.
📋 Key Facts
- The conference takes place from March 2-4, 2026, in Boston, Massachusetts.
- Dr. Andre Simon, VP of Clinical Affairs, is scheduled to give three separate presentations.
- The filing is a standard Item 7.01 Regulation FD disclosure to furnish a press release.
Picard Medical, Inc. announced its participation in the 'Hands-On Training Day' at the Technology and Heart Failure Therapeutics 2026 conference. The event is scheduled for March 1, 2026, in Boston, Massachusetts.
📋 Key Facts
- The company will participate in the Technology and Heart Failure Therapeutics 2026 conference.
- The specific event is a 'Hands-On Training Day' on March 1, 2026.
- The filing was made under Item 7.01 (Regulation FD Disclosure).
- A press release regarding the event was furnished as Exhibit 99.1.